<DOC>
	<DOCNO>NCT00006591</DOCNO>
	<brief_summary>The purpose study determine treatment anti-HIV drug contain ritonavir Agenerase safe low level HIV blood patient fail anti-HIV drug treatment contain nelfinavir .</brief_summary>
	<brief_title>Ritonavir Agenerase Treatment Patients Who Have Failed Previous Anti-HIV Treatment</brief_title>
	<detailed_description>HIV-infected patient treat ritonavir-enhanced Agenerase regimen .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are 18 year age old . Are HIVpositive . Have viral load ( level HIV body ) 1,000 copies/ml . Have 12 week prior antiHIV drug treatment . Have fail previous antiHIV treatment contain nelfinavir protease inhibitor . Are responsive Agenerase . Are able follow study requirement . Exclusion Criteria Patients eligible study : Are intolerant ritonavir ( antiHIV drug ) . Have problem absorption . Have liver disease damage . Have pancreatic disease damage . Have take protease inhibitor nelfinavir . Are receive investigational drug device another study . Are pregnant breastfeeding . Currently use triazolam , astemizole , ergot medication , cisapride , midazolam , bepridil , rifampin , terfenadine , pimozide . Have bleed disorder . Have previously treat Agenerase . Are receive nonnucleosides .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>VX 478</keyword>
	<keyword>Salvage Therapy</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Drug Monitoring</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>